SBC is an uncommon tumor that is often well-differentiated and seen in younger women. Contrary to prior reports, they are frequently hormone receptor-positive. Compared to IDC, overall survival is improved. J. Surg. Oncol. 2016;113:721-725. © 2016 Wiley Periodicals, Inc.

Malignant ascites (MA) carries a poor prognosis. It can have a significant impact on quality of life (QOL), with increasing abdominal distention, pain, and dyspnea. Diuretics typically do not work well for MA. Paracentesis is effective in providing temporary symptom relief but requires frequent repeat procedures. Options for durable symptom management include indwelling catheters, peritoneal ports, peritoneovenous shunts, intraperitoneal (i.p.) catumaxomab, and hyperthermic i.p. chemotherapy. These interventions do not necessarily improve overall survival but may improve QOL. K E Y W O R D S catumaxomab, hyperthermic intraperitoneal chemotherapy, paracentesis, peritoneal carcinomatosis 1 | INTRODUCTION Malignant ascites (MA) is not among the more common indications for palliative surgical consultation, such as bowel obstruction,gastrointestinal bleeding, and wound problems. However, MA, when refractory to medical management or paracentesis, can represent a challenging palliative clinical scenario. There is a paucity of clinical trials or even prospective studies to guide treatment. As with other indications for palliative surgical consultation, the optimal treatment is often a balance between the known risks of a given procedure and the potential for symptom improvement. Of course, the goals of the patient, in the background of their prognosis and treatment options for their malignancy, ultimately guide decision making. In this review article, we will cover the signs and symptoms, etiology, diagnosis, treatment options, and associated outcomes for patients with MA.MA is a poor prognostic indicator and has a detrimental effect on quality of life (QOL). Reported prognosis for survival at the time of diagnosis of MA varies from 1 to 6 months. 1-5 Although there have been advances in chemotherapy, newer studies still have found a median survival of 5.6 months. 6 Approximately 11% of patients survive greater than 6 months once MA develops. 7 However, MA secondary to ovarian cancer is associated with a longer life expectancy than MA from other types of cancer and has been reported up to 10 to 24 months. 7 The end-stage nature of this presentation requires careful evaluation and deliberation regarding options for management. | ETIOLOGYAlthough MA is most commonly associated with ovarian cancer (25%-28% of all cases of MA), 6,8 it is also associated with colorectal, pancreatic, uterine, gastric, and primary peritoneal cancers, as well as extra-abdominal tumors such as lymphoma, lung, and breast cancer. 1,3,6,8,9 Given the predominance of ovarian cancer as well as the association with breast cancer, MA occurs more commonly in women than men. 5,6 Up to 20% of cases of MA have an unknown primary tumor. 3,6 MA is the presenting sign or symptom of malignancy in about 50% of cases. 3,10 Patients with gastric and ovarian cancer are more likely to have an MA at the time of the first diagnosis, whereas patients with breast cancer tend to develop MA months or even years after initial diagnosis and treatment. 6 MA occurs via a diff...

No abstract

Background Bronchoscopy with transbronchial lung biopsy (TBLB) is commonly used as a diagnostic tool for pulmonary disease. Hemorrhage is a major complication of TBLB. While pulmonary hypertension (PH) is considered a risk factor, evidence supporting this is limited. In this study, we compare complications of TBLB in patients with PH to those without PH. Material and methods We performed a retrospective review of patients who underwent TBLB in our institution from January 2010 to May 2016. PH and non-PH groups were compared with respect to patient demographics, biopsy guidance, number of lobes biopsied (single or multiple), positive pressure ventilation, pre-and post-procedure diagnoses, and complications. Complications were defined as major hemorrhage, prolonged intubation, and reintubation within 72 hours from TBLB. Results The PH group had 45 patients with a mean age of 71 ± 14 years, and the non-PH group had 349 patients with a mean age of 63 ± 14 years. There were no significant differences with regards to gender, pre-procedure anticoagulation and antiplatelet agents, biopsy guidance, or number of lobes biopsied (p > 0.371). There was no significant difference in the occurrence of major hemorrhage between the two groups (p = 0.491). Prolonged intubation occurred more frequently in the PH group (p = 0.007). Conclusions There appears to be no increased risk of post-procedure hemorrhage with TBLB in patients with mild PH. There is, however, an increased risk of post-procedure prolonged intubation in these patients.

diagnoses in the first 162 T0 scans (3%), 4 of 5 were AAs. Of these cancers, 60% were stage I vs 63% in NLST.Conclusion: UIHSP demonstrated a right-shift in Lun-gRADS scores and a higher LC rate which raises the question: Do CMS guidelines properly align with LC risk in minority populations such as UIHSP? Moreover, UIHSP had a higher LungRADS 3 (15.4% vs 1.2%) and 4 (15.4% vs 4.6%). LC diagnostic rates were also 3x NLST (3% vs 1%). These are consistent with the known higher LC incidence and mortality among AA men compared to C men (incidence 87.3 vs. 72.5; mortality 70.1 vs. 57.8 per 100,000).